Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals

Despite a few setbacks, Vertex Pharmaceuticals (NASDAQ: VRTX) performed pretty well last year, although it lagged the S&P 500. However, things could be very different in 2026. Thanks to several catalysts and potential regulatory progress, the biotech could see its shares jump significantly this year. Here's why 2026 could be the year of Vertex Pharmaceuticals.Image source: Getty Images.Vertex Pharmaceuticals' strategy is to develop medicines in areas with high unmet needs. The company has dominated the market for cystic fibrosis (CF) -- a rare disease that affects internal organs -- for over a decade. But the biotech has sought to diversify its product lineup, and it has been somewhat successful in recent years. Vertex Pharmaceuticals could make another giant leap toward that goal this year. The company's late-stage pipeline features zimislecel, inaxaplin, and povetacicept. Zimislecel is an investigational medicine for type 1 diabetes.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool